Outcomes of switching anti-TNF drugs in rheumatoid arthritis-a study based on observational data from the finnish register of biological treatment (ROB-FIN)

Clinical Rheumatology

Volumn 30, Issue 11, 2011, Pages 1447-1454

  Virkki, Liisa M ^a   Valleala, Heikki ^a   Takakubo, Yuya ^a,b   Vuotila, Jorma ^c   Relas, Heikki ^a   Komulainen, Riitta ^d   Koivuniemi, Riitta ^a   Yli Kerttula, Urpo ^e,f   Mali, Markku ^g   Sihvonen, Susanna ^f,h   Krogerus, Maija Liisa ^i,j   Jukka, Eero ^k   Nyrhinen, Satu ^l   Konttinen, Yrjö T ^a,b,m   Nordström, Dan C ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b ORTON ORTHOPAEDIC HOSPITAL   (Finland)

^c Kuusankosken Aluesairaala   (Finland)

^d Riihimäki Regional Hospital   (Finland)

^e SEINÄJOKI CENTRAL HOSPITAL   (Finland)

^f TAMPERE UNIVERSITY HOSPITAL   (Finland)

^g TURKU UNIVERSITY HOSPITAL   (Finland)

^h Mänttä Regional Hospital   (Finland)

ⁱ LAPLAND CENTRAL HOSPITAL   (Finland)

^j Lansi Pohja Central Hospital   (Finland)

^k Rauma Regional Hospital   (Finland)

^l RHEUMATISM FOUNDATION HOSPITAL   (Finland)

^m COXA Hospital for Joint Replacement ^*  (Finland)

more..

Author keywords

Adverse event; Biological therapy; Lack of effectiveness; Rheumatoid arthritis; Tumor necrosis factor alpha

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; ETANERCEPT; INFLIXIMAB;

ADULT; AGED; ARTICLE; BIOLOGICAL THERAPY; DISEASE ACTIVITY; DRUG EFFICACY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ECZEMA; FEMALE; HUMAN; INJECTION SITE REACTION; JOINT SWELLING; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; FINLAND; HUMANS; IMMUNOGLOBULIN G; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RECEPTORS, TUMOR NECROSIS FACTOR; REGISTRIES; TREATMENT OUTCOME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 80755132171     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1779-1     Document Type: Article

References (44)

1. MH Buch PG Conaghan MA Quinn SJ Bingham D Veale P Emery 2004 True infliximab resistance in rheumatoid arthritis: a role for lymphotoxin alpha? Ann Rheum Dis 63 1344 1346 15033655 10.1136/ard.2003.014878 1:STN:280: DC%2BD2cvoslShsQ%3D%3D (Pubitemid 39273521)
2. R Klaasen RM Thurlings CA Wijbrandts AW van Kuijk D Baeten DM Gerlag PP Tak 2009 The relationship between synovial lymphocyte aggregates and the clinical response to infliximab in rheumatoid arthritis: a prospective study Arthritis Rheum 60 3217 3224 19877042 10.1002/art.24913 1:CAS:528: DC%2BD1MXhsFentL7F
3. D Tracey L Klareskog EH Sasso JG Salfeld PP Tak 2008 Tumor necrosis factor antagonist mechanisms of action: a comprehensive review Pharmacol Ther 117 244 279 18155297 10.1016/j.pharmthera.2007.10.001 1:CAS:528: DC%2BD1cXhtV2it74%3D
4. S Mpofu F Fatima RJ Moots 2005 Anti-TNF-alpha therapies: they are all the same (aren't they?) Rheumatology (Oxford) 44 271 273 10.1093/rheumatology/ keh483 1:CAS:528:DC%2BD2MXhslSksrc%3D (Pubitemid 40361279)
5. JR Lutt A Deodhar 2008 Rheumatoid arthritis: strategies in the management of patients showing an inadequate response to TNFalpha antagonists Drugs 68 591 606 18370440 10.2165/00003495-200868050-00003 1:CAS:528:DC%2BD1cXmsV2ntbs%3D (Pubitemid 351451539)
6. DE Furst EC Keystone R Fleischmann P Mease FC Breedveld JS Smolen JR Kalden J Braun B Bresnihan GR Burmester F De Benedetti T Dörner P Emery A Gibofsky A Kavanaugh B Kirkham MH Schiff J Sieper N Singer PL Van Riel ME Weinblatt MH Weisman K Winthrop 2010 Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2009 Ann Rheum Dis 69 Suppl 1 i2 i29 19995740 10.1136/ard.2009.123885 1:CAS:528:DC%2BC3cXhtFOlsbs%3D
7. R van Vollenhoven A Harju S Brannemark L Klareskog 2003 Treatment with infliximab (Remicade) when etanercept (Enbrel) has failed or vice versa: data from the STURE registry showing that switching tumour necrosis factor alpha blockers can make sense Ann Rheum Dis 62 1195 1198 14644858 10.1136/ard.2003. 009589 (Pubitemid 37500626)
8. O Brocq C Albert C Roux D Gerard V Breuil LE Ziegler 2004 Adalimumab in rheumatoid arthritis after failed infliximab and/or etanercept therapy: experience with 18 patients Joint Bone Spine 71 601 603 15589452 10.1016/j.jbspin.2004.07.009 1:STN:280:DC%2BD2M%2FhsFWltA%3D%3D (Pubitemid 39626739)
9. Y Yazici D Erkan 2004 Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed? Ann Rheum Dis 63 607 608 15082503 1:STN:280:DC%2BD2c7osFShtw%3D%3D (Pubitemid 38530216)
10. G Cohen N Courvoisier JD Cohen S Zaltni J Sany B Combe 2005 The efficiency of switching from infliximab to etanercept and vice-versa in patients with rheumatoid arthritis Clin Exp Rheumatol 23 795 800 16396697 1:STN:280:DC%2BD28%2FhsFCgtQ%3D%3D (Pubitemid 43040507)
11. MC Wick S Ernestam S Lindblad J Bratt L Klareskog RF van Vollenhoven 2005 Adalimumab (Humira) restores clinical response in patients with secondary loss of efficacy from infliximab (Remicade) or etanercept (Enbrel): results from the STURE registry at Karolinska University Hospital Scand J Rheumatol 34 353 358 16234182 10.1080/03009740510026887 1:CAS:528:DC%2BD2MXht1GhtLzF (Pubitemid 41545907)
12. JJ Gomez-Reino L Carmona 2006 Switching TNF antagonists in patients with chronic arthritis: an observational study of 488 patients over a four-year period Arthritis Res Ther 8 R29 16507128 10.1186/ar1881
13. SN Nikas PV Voulgari Y Alamanos CG Papadopoulos AI Venetsanopoulos AN Georgiadis AA Drosos 2006 Efficacy and safety of switching from infliximab to adalimumab: a comparative controlled study Ann Rheum Dis 65 257 260 15975964 10.1136/ard.2005.039099 1:CAS:528:DC%2BD28XhsFeitb8%3D (Pubitemid 43132005)
14. E Solau-Gervais N Laxenaire B Cortet S Dubucquoi B Duquesnoy RM Flipo 2006 Lack of efficacy of a third tumour necrosis factor alpha antagonist after failure of a soluble receptor and a monoclonal antibody Rheumatology (Oxford) 45 1121 1124 10.1093/rheumatology/kel054 1:CAS:528:DC%2BD28XhtVWlt7fJ (Pubitemid 44542100)
15. S Bombardieri AA Ruiz P Fardellone P Geusens F McKenna K Unnebrink U Oezer S Kary H Kupper GR Burmester Research in Active Rheumatoid Arthritis (ReAct) Study Group 2007 Effectiveness of adalimumab for rheumatoid arthritis in patients with a history of TNF-antagonist therapy in clinical practice Rheumatology (Oxford) 46 1191 1199 10.1093/rheumatology/kem091 1:CAS:528:DC%2BD2sXosVSjt74%3D (Pubitemid 47053782)
16. MH Buch SJ Bingham V Bejarano D Bryer J White R Reece M Quinn P Emery 2007 Therapy of patients with rheumatoid arthritis: outcome of infliximab failures switched to etanercept Arthritis Rheum 57 448 453 17394231 10.1002/art.22617 1:CAS:528:DC%2BD2sXltFOjsbk%3D (Pubitemid 46682532)
17. E Di Poi A Perin MP Morassi M Del Frate GF Ferraccioli S De Vita 2007 Switching to etanercept in patients with rheumatoid arthritis with no response to infliximab Clin Exp Rheumatol 25 85 87 17417995 (Pubitemid 46477490)
18. DE Furst N Gaylis V Bray E Olech D Yocum J Ritter M Weisman DJ Wallace J Crues D Khanna G Eckel N Yeilding P Callegari S Visvanathan J Rojas R Hegedus L George K Mamun K Gilmer O Troum 2007 Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study Ann Rheum Dis 66 893 899 17412737 10.1136/ard.2006.068304 1:CAS:528:DC%2BD2sXotlSitL4%3D (Pubitemid 46999789)
19. E Hjardem M ∅stergaard J Pødenphant U Tarp LS Andersen J Bing E Peen HM Lindegaard VS Ringsdal A Rødgaard J Skøt A Hansen HH Mogensen J Unkerskov ML Hetland 2007 Do rheumatoid arthritis patients in clinical practice benefit from switching from infliximab to a second tumor necrosis factor alpha inhibitor? Ann Rheum Dis 66 1184 1189 17389656 10.1136/ard.2006.054742 1:CAS:528:DC%2BD2sXhtVKltL7J (Pubitemid 47309735)
20. KL Hyrich M Lunt KD Watson DP Symmons AJ Silman 2007 Outcomes after switching from one anti-tumor necrosis factor alpha agent to a second anti-tumor necrosis factor alpha agent in patients with rheumatoid arthritis: results from a large UK national cohort study Arthritis Rheum 56 13 20 17195186 10.1002/art.22331 1:CAS:528:DC%2BD2sXhsFaisrw%3D (Pubitemid 46106174)
21. F Iannone F Trotta C Montecucco R Giacomelli M Galeazzi M Matucci-Cerinic C Ferri M Cutolo L Maria Bambara G Triolo G Ferraccioli G Valentini G Lapadula 2007 Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects Ann Rheum Dis 66 249 252 16837489 10.1136/ard.2006.058776 1:CAS:528:DC%2BD2sXislChsbw%3D (Pubitemid 46226063)
22. JA Karlsson LE Kristensen MC Kapetanovic A Gülfe T Saxne P Geborek 2008 Treatment response to a second or third TNF-inhibitor in RA: results from the South Swedish Arthritis Treatment Group Register Rheumatology (Oxford) 47 507 513 10.1093/rheumatology/ken034 1:CAS:528:DC%2BD1cXmslKhtbw%3D
23. M Blom W Kievit J Fransen IH Kuper AA den Broeder CM De Gendt TL Jansen HL Brus MA van de Laar PL van Riel 2009 The reason for discontinuation of the first tumor necrosis factor (TNF) blocking agent does not influence the effect of a second TNF blocking agent in patients with rheumatoid arthritis J Rheumatol 36 2171 2177 19723902 10.3899/jrheum.090054 1:CAS:528:DC%2BD1MXhsVams7bP
24. F Conti R Scrivo FR Spinelli S Truglia L Magrini M Di Franco F Ceccarelli G Valesini 2009 Outcome in patients with rheumatoid arthritis switching TNF-alpha antagonists: a single center, observational study over an 8-year period Clin Exp Rheumatol 27 540 541 19604456 1:STN:280:DC%2BD1Mvoslahsw%3D%3D
25. JS Smolen J Kay MK Doyle R Landewé EL Matteson J Wollenhaupt N Gaylis FT Murphy JS Neal Y Zhou S Visvanathan EC Hsia MU Rahman for the GO-AFTER study investigators 2009 Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial Lancet 374 210 221 19560810 10.1016/S0140-6736(09)60506-7 1:CAS:528: DC%2BD1MXos12ru7o%3D
26. L Konttinen V Honkanen T Uotila J Pöllänen M Waahtera M Romu K Puolakka M Vasala A Karjalainen R Luukkainen DC Nordström 2006 Biological treatment in rheumatic diseases: results from a longitudinal surveillance: adverse events Rheumatol Int 26 916 922 16402217 10.1007/s00296-005-0097-9 1:STN:280:DC%2BD28zot12qsQ%3D%3D (Pubitemid 43962122)
27. L Konttinen E Kankaanpää R Luosujärvi H Blåfield K Vuori M Hakala V Rantalaiho E Savolainen T Uutela D Nordström 2006 Effectiveness of anakinra in rheumatic disease in patients naive to biological drugs or previously on TNF blocking drugs: an observational study Clin Rheumatol 25 882 884 16552464 10.1007/s10067-006-00243-0 (Pubitemid 44473158)
28. DC Nordström L Konttinen M Korpela T Tiippana-Kinnunen K Eklund S Forsberg K Ilva O Kaipiainen-Seppänen T Malmi T Ylä-Kerttula V Honkanen 2006 Classic disease modifying anti-rheumatic drugs (DMARDs) in combination with infliximab. The Finnish experience Rheumatol Int 26 741 748 16205925 10.1007/s00296-005-0054-7 (Pubitemid 43725468)
29. L Konttinen R Tuompo T Uusitalo R Luosujärvi K Laiho J Lähteenmäki M Puurtinen-Vilkki R Lanteri S Kortelainen H Karilainen T Varjolahti-Lehtinen D Nordström 2007 Anti-TNF therapy in the treatment of ankylosing spondylitis: the Finnish experience; ROB-FIN Study Group Clin Rheumatol 26 1693 1700 17332979 10.1007/s10067-007-0574-5
30. LM Virkki YT Konttinen R Peltomaa K Suontama R Saario K Immonen J Jäntti T Tuomiranta P Nykänen R Hämeenkorpi S Heikkilä P Isomäki D Nordström 2008 Cost-effectiveness of infliximab in the treatment of rheumatoid arthritis in clinical practice Clin Exp Rheumatol 26 1059 1066 19210870 1:STN:280:DC%2BD1M7jsFCrsA%3D%3D
31. LM Virkki BC Sumathikutty M Aarnio H Valleala R Heikkilä M Kauppi K Karstila L Pirilä P Ekman S Salomaa M Romu J Seppälä H Niinisalo YT Konttinen DC Nordström 2010 Biological therapy for psoriatic arthritis in clinical practice: outcomes up to 2 years J Rheumatol 37 2362 2368 20716655 10.3899/jrheum.091477
32. Hakala M, Hannonen P, Helve T, Korpela M, Mattila K, Möttonen T, Varis T (updated 2009) Rheumatoid arthritis. Current Care guideline 2003. www.kaypahoito.fi. Accessed 14 Apr 2011
33. B Haraoui EC Keystone JC Thorne JE Pope I Chen CG Asare JA Leff 2004 Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept J Rheumatol 31 2356 2359 15570634 1:CAS:528: DC%2BD2MXivFKrsA%3D%3D (Pubitemid 39603081)
34. GJ Wolbink M Vis W Lems AE Voskuyl E de Groot MT Nurmohamed S Stapel PP Tak L Aarden B Dijkmans 2006 Development of antiinfliximab antibodies and relationship to clinical response in patients with rheumatoid arthritis Arthritis Rheum 54 711 715 16508927 10.1002/art.21671
35. MH Buch SJ Bingham D Bryer P Emery 2007 Long-term infliximab treatment in rheumatoid arthritis: subsequent outcome of initial responders Rheumatology (Oxford) 46 1153 1156 10.1093/rheumatology/kem075 1:CAS:528:DC%2BD2sXosVSjtrk%3D (Pubitemid 47050620)
36. K Bendtzen P Geborek M Svenson L Larsson MC Kapetanovic T Saxne 2006 Individualized monitoring of drug bioavailability and immunogenicity in rheumatoid arthritis patients treated with the tumor necrosis factor alpha inhibitor infliximab Arthritis Rheum 54 3782 3789 17133559 10.1002/art.22214 1:CAS:528:DC%2BD2sXktlanug%3D%3D (Pubitemid 44955878)
37. TR Radstake M Svenson AM Eijsbouts FH van den Hoogen C Enevold PL van Riel K Bendtzen 2009 Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis Ann Rheum Dis 68 1739 1745 19019895 10.1136/ard.2008.092833 1:CAS:528:DC%2BD1MXhs1WitbfP
38. AE van der Bijl FC Breedveld CE Antoni JR Kalden S Kary GR Burmester C Beckmann K Unnebrink H Kupper 2008 An open-label pilot study of the effectiveness of adalimumab in patients with rheumatoid arthritis and previous infliximab treatment: relationship to reasons for failure and anti-infliximab antibody status Clin Rheumatol 27 1021 1028 18350329 10.1007/s10067-008-0866-4
39. GM Bartelds CA Wijbrandts MT Nurmohamed S Stapel WF Lems L Aarden BA Dijkmans PP Tak GJ Wolbink 2007 Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis Ann Rheum Dis 66 921 926 17301106 10.1136/ard.2006.065615 1:CAS:528:DC%2BD2sXotlSitLk%3D (Pubitemid 46999794)
40. AP Rozin 2004 Infliximab efficiency and failure Ann Rheum Dis 63 751 752 15140791 10.1136/ard.2003.016824 1:STN:280:DC%2BD2c3ktFKntQ%3D%3D (Pubitemid 38850469)
41. PJ Anderson 2005 Tumor necrosis factor inhibitors: clinical implications of their different immunogenicity profiles Semin Arthritis Rheum 34 Suppl 1 19 22 15852250 10.1016/j.semarthrit.2005.01.005 1:CAS:528:DC%2BD2MXjtVyrtLk%3D
42. GM Bartelds CA Wijbrandts MT Nurmohamed S Stapel WF Lems L Aarden BA Dijkmans PP Tak GJ Wolbink 2010 Anti-infliximab and anti-adalimumab antibodies in relation to response to adalimumab in infliximab switchers and anti-tumour necrosis factor naive patients: a cohort study Ann Rheum Dis 69 817 821 19581278 10.1136/ard.2009.112847 1:CAS:528:DC%2BC3cXntlOks7w%3D
43. JS Smolen ME Weinblatt 2008 When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? Ann Rheum Dis 67 1497 1498 18854512 10.1136/ard.2008.098111
44. E Villeneuve B Haraoui 2010 To switch or to change class-the biologic dilemma in rheumatoid arthritis Nat Rev Rheumatol 6 301 305 20386564 10.1038/nrrheum.2010.45 1:CAS:528:DC%2BC3cXlsVSqt7k%3D